

May 18, 2015



# VolitionRx CEO Cameron Reynolds to Present Informational Webinar

**Presentation and Live Q&A on Wednesday, May 20 at 2pm US EDT**

NAMUR, Belgium, May 18, 2015 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present an informational webcast, being held May 20, to provide interested parties with information on VolitionRx and its clinical programs assessing its blood-based Nucleosomics® technology platform for the detection of the most prevalent cancers.

During the webcast Mr. Reynolds will outline the importance of early cancer detection, differentiators of VolitionRx's diagnostics platform, and how VolitionRx's NuQ® tests are addressing the global need for improved, non-invasive, accurate, and cost-effective cancer diagnostics. A live question and answer session will follow the presentation.

Details of the webcast are as follows:

**Event:** VolitionRx Webcast  
**Date:** Wednesday, May 20, 2015  
**Time:** 2:00 p.m. EDT

Participants can reserve their spot by registering at <http://volitionrx.dealflow.com/webcast/>. Participants unable to join can register and will be sent the recording.

## About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website ([www.volitionrx.com](http://www.volitionrx.com)) or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

## Media Contacts

Charlotte Reynolds, VolitionRx  
[Charlotte.Reynolds@volitionrx.com](mailto:Charlotte.Reynolds@volitionrx.com)

Telephone: +44 (0) 795 217 7498

Kirsten Thomas, The Ruth Group

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

Telephone: +1 (646) 536-7014

## **Investor Contacts**

Scott Powell, VolitionRx

[S.Powell@volitionrx.com](mailto:S.Powell@volitionrx.com)

Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

Telephone: +1 (646) 536-7012

## **Safe Harbor Statement**

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's blood-based diagnostic test as well as the Company's ability to develop and successfully commercialize such test platform for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-ceo-cameron-reynolds-to-present-informational-webinar-300084662.html>

SOURCE VolitionRx Ltd